Sawicki Mark W's Form 4 filing
Cryoport, Inc. (CYRX) · filed Mar 19, 2024
- Accession no.
- 0001104659-24-036284
- Filed
- Mar 19, 2024
- Trade date
- Mar 9-15, 2024
- Filing delay
- 10 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $43.4K. It was filed 10 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Sawicki Mark WCIK 0001848218 | Officer (Chief Scientific Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 9, 2024 | Common Stock | MOption exerciseAcquired | +2,666 | $0.00F1 | $0 | 75,791 | Direct | |
| Mar 11, 2024 | Common Stock | SSaleDisposed | −1,418 | $16.35 | −$23,184.3 | 74,373 | Direct | |
| Mar 15, 2024 | Common Stock | SSaleDisposed | −1,312 | $15.43 | −$20,244.16 | 73,061 | Direct | |
| Mar 15, 2024 | Common Stock | AGrant or awardAcquired | +5,750 | $0.00F3 | $0 | 78,811 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 9, 2024 | Common Stock | MOption exerciseDisposed | −2,666 | $0.00 | $0 | 2,667 | Direct | |
| Mar 15, 2024 | Common Stock | AGrant or awardAcquired | +11,500 | $0.00 | $0 | 11,500 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Represents the conversion of restricted stock rights to shares of common stock upon vesting. Each restricted stock right represents a contingent right to receive one share of CYRX common stock.
Referenced by the price of 1 transaction in Table I.
- F3
Represents restricted stock rights, which are a contingent right to receive one share of CYRX common stock, that vest in four equal annual installments beginning March 15, 2025.
Referenced by the price of 1 transaction in Table I.